Looking at p53: theoretical implications and methodological aspects.
作者信息
Opalka B, Kasimir-Bauer S
机构信息
Klinikum der Universität (GHS) Essen.
出版信息
Arch Toxicol Suppl. 1997;19:17-28. doi: 10.1007/978-3-642-60682-3_2.
PMID:9079191
Abstract
摘要
相似文献
1
Looking at p53: theoretical implications and methodological aspects.
Arch Toxicol Suppl. 1997;19:17-28. doi: 10.1007/978-3-642-60682-3_2.
2
The p53 tumour suppressor gene and product.
Cancer Surv. 1992;12:59-79.
3
To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
Hum Exp Toxicol. 1995 Feb;14(2):222-5. doi: 10.1177/096032719501400213.
4
p53 selected as molecule of the year 1993.
Pharm World Sci. 1994 Feb 18;16(1):1. doi: 10.1007/BF01870930.
5
p53: balancing tumour suppression and implications for the clinic.
Eur J Cancer. 2009 Sep;45 Suppl 1:217-34. doi: 10.1016/S0959-8049(09)70037-1.
6
On the expression of the p53 protein in human cancer.
Mol Biol Rep. 1994 Jan;19(1):23-9. doi: 10.1007/BF00987319.
7
[TP53 tumor suppressor gene: 20 years (and ten thousand mutations) later].
Bull Cancer. 2000 Jan;87(1):11-8.
8
p53: from clinical significance to significance in the clinic?
N Z Med J. 1997 Sep 26;110(1052):347-8.
9
The expanding universe of p53 targets.
Nat Rev Cancer. 2009 Oct;9(10):724-37. doi: 10.1038/nrc2730.
10
p53 and human cancers.
Br Med Bull. 1994 Jul;50(3):582-99. doi: 10.1093/oxfordjournals.bmb.a072911.
Zotero 插件